Published: 23 January 2022
Author(s): Jade Heitz, Jerome Razanamahery, Sylvain Audia, Jean-Baptiste Bour, Julien Guy, Sabine Berthier, Vanessa Leguy, Thibault Ghesquiere, Barbara Nicolas, Maxime Samson, Bernard Bonnotte
Issue: May 2022
Section: Letter to the Editor

B-depleting therapies increase the risk of severe COVID-19 [1] and have been shown to induce an impaired immune response to the SARS-COV2 vaccine [2]. There is a lack of data exploring the T-cell response to SARS COV2 vaccine [3,4], especially since it may be preserved in patients treated with rituximab [5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.